Business Description
CanSino Biologics Inc
SIC : 2836
ISIN : CNE100003F01
Share Class Description:
STU:CJH: Class HTotal Employee Number:
1,134Compare
Compare
Traded in other countries / regions
06185.Hong Kong688185.ChinaCJH.GermanyCASBF.USA IPO Date
2019-04-09Description
CanSino Biologics Inc. is a Chinese biopharmaceutical company that researches, develops, manufactures, and commercializes human vaccines. Its commercial portfolio includes Menhycia and Menphecia for meningococcal disease, the pneumococcal vaccine iPneucia, and Convidecia, an inhaled adenovirus-based COVID-19 vaccine developed with the Beijing Institute of Biotechnology. The company also markets Ad5-EBOV for Ebola. Its pipeline spans preventive vaccines against tetanus, diphtheria, pertussis, poliomyelitis, pneumococcal disease, tuberculosis, and shingles, along with earlier-stage candidates targeting influenza and other infectious diseases. CanSino sells primarily to public health authorities and vaccination programs in China, which accounts for the large majority of its revenue, and it has pursued international distribution and licensing agreements in emerging markets. Revenue comes from vaccine sales and, to a lesser extent, collaboration and licensing arrangements with partners. The company is headquartered in Tianjin and listed in Hong Kong and Shanghai.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.88 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 13.62 | |||||
Interest Coverage | 1.34 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.45 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.5 | |||||
3-Year FCF Growth Rate | 61.9 | |||||
3-Year Book Growth Rate | -10.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 205.18 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 30.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.23 | |||||
9-Day RSI | 57.17 | |||||
14-Day RSI | 54.5 | |||||
3-1 Month Momentum % | 8.26 | |||||
6-1 Month Momentum % | -30.76 | |||||
12-1 Month Momentum % | -53.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.31 | |||||
Quick Ratio | 3.81 | |||||
Cash Ratio | 2.46 | |||||
Days Inventory | 398.56 | |||||
Days Sales Outstanding | 236.18 | |||||
Days Payable | 53.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 6.91 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.39 | |||||
Operating Margin % | 3 | |||||
Net Margin % | 3.23 | |||||
EBITDA Margin % | 6 | |||||
FCF Margin % | -10.41 | |||||
OCF Margin % | 3.07 | |||||
ROE % | 0.81 | |||||
ROA % | 0.55 | |||||
ROIC % | 0.71 | |||||
3-Year ROIIC % | -71.93 | |||||
ROC (Joel Greenblatt) % | 2.38 | |||||
ROCE % | 1.23 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 152.1 | |||||
Forward PE Ratio | 35.07 | |||||
PE Ratio without NRI | 480.74 | |||||
PS Ratio | 4.79 | |||||
PB Ratio | 1.15 | |||||
Price-to-Tangible-Book | 1.31 | |||||
EV-to-EBIT | 140.66 | |||||
EV-to-EBITDA | 140.66 | |||||
EV-to-Revenue | 8.43 | |||||
EV-to-FCF | -44.65 | |||||
Price-to-GF-Value | 0.45 | |||||
Price-to-Graham-Number | 5.47 | |||||
| Price-to-Net-Current-Asset-Value | 4.52 | |||||
Earnings Yield (Greenblatt) % | 0.71 | |||||
FCF Yield % | -1.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CanSino Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 151.487 | ||
| EPS (TTM) (€) | 0.02 | ||
| Beta | 0.7949 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.6 | ||
| Volatility % | 41.9 | ||
| 14-Day RSI | 54.5 | ||
| 14-Day ATR (€) | 0.174832 | ||
| 20-Day SMA (€) | 3.122 | ||
| 12-1 Month Momentum % | -53.71 | ||
| 52-Week Range (€) | 2.28 - 5.675 | ||
| Shares Outstanding (Mil) | 247.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CanSino Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CanSino Biologics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-28 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | 3.82 (-4.50%) | ||
| General meeting for 2025 | 2026-06-10 13:30 | 2.48 (-0.80%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 3.46 (-1.70%) | ||
| Annual report for 2025 | 2026-03-31 | 3.54 (+2.49%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 3.40 (-2.69%) | ||
| Third quarter earnings results for 2025 | 2025-10-28 | 4.74 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 5.17 (+1.57%) | ||
| General meeting for 2024 | 2025-06-04 09:15 | 3.72 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-04-30 | 3.40 (+0.00%) |
Show
Entries
CanSino Biologics Inc Frequently Asked Questions
What is CanSino Biologics Inc(STU:CJH)'s stock price today?
The current price of STU:CJH is €3.12. The 52 week high of STU:CJH is €5.68 and 52 week low is €2.28.
When is next earnings date of CanSino Biologics Inc(STU:CJH)?
The next earnings date of CanSino Biologics Inc(STU:CJH) is 2026-10-28 Est..
Does CanSino Biologics Inc(STU:CJH) pay dividends? If so, how much?
CanSino Biologics Inc(STU:CJH) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers